L. Johnson

发表

(R) and (S) RS 56532: Mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity

E. Wong, R. Eglen, D. Bonhaus, 1994, Neuropharmacology.

The action of SDZ 205,557 at 5‐hydroxytryptamine (5‐HT3 and 5‐HT4) receptors

E. Wong, R. Alvarez, R. Eglen, 1993, British journal of pharmacology.

Cardiovascular effects of nepicastat (RS-25560-197), a novel dopamine beta-hydroxylase inhibitor.

R. Eglen, W. Stanley, K. Lee, 1998, Journal of cardiovascular pharmacology.

Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylase

R. Eglen, B. Li, D. Bonhaus, 1997, British journal of pharmacology.

RS 39604: a potent, selective and orally active 5‐HT4 receptor antagonist

R. Eglen, E. Leung, L. Johnson, 1995, British journal of pharmacology.

Pharmacological characterization of two novel and potent 5‐HT4 receptor agonists, RS 67333 and RS 67506, in vitro and in vivo

R. Eglen, D. Bonhaus, E. Leung, 1995, British journal of pharmacology.

Rs-100235: A high affinity 5-HT4 receptor antagonist

E. Wong, R. Eglen, D. Bonhaus, 1995 .

Pharmacological characterization of RS 25259‐197, a novel and selective 5‐HT3 receptor antagonist, in vivo

R. Eglen, W. Smith, R. Clark, 1995, British journal of pharmacology.

RS 42358-197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo.

R. Eglen, W. Smith, C. Lee, 1993, The Journal of pharmacology and experimental therapeutics.

A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.

A. Oza, S. Welch, Q. Chu, 2012 .

RS 23597‐190: a potent and selective 5‐HT4 receptor antagonist

E. Wong, K. Bley, R. Eglen, 1993, British journal of pharmacology.